Clinical Trial News and Research

RSS

Study evaluates role of PET/CT in selecting candidates for peptide receptor radionuclide therapy

A new study published in The Journal of Nuclear Medicine evaluated the role of 68Ga-DOTATATE positron emission tomography/computed tomography in selecting neuroendocrine tumor patients who may benefit from peptide receptor radionuclide therapy.

9 Oct 2019

Rice bran supplement for infants provides more nutrients, reduces diarrhea

Malnutrition is prevalent on a global scale and has numerous negative consequences for children during the first five years of life. For some children, it can mean struggling with health issues for life or a higher risk of death among those under five years of age.

8 Oct 2019

Differences at the single-cell level can predict responses to BRAF inhibitor therapy

Patients with advanced melanoma have been able to live longer because of several newly approved targeted treatment options, including BRAF and MEK inhibitors. However, patients will often have different responses to the same treatment due to genetic variability.

8 Oct 2019

UTHealth: Psychedelic drug being studied to relieve treatment-resistant depression

Psilocybin, a psychedelic drug believed to help rewire the brain, is now being studied to relieve treatment-resistant depression at The University of Texas Health Science Center at Houston (UTHealth) as part of a global Phase II clinical trial.

8 Oct 2019

New experimental growth factor drug appears to prevent worsening of osteoarthritis

More than 10 percent of Americans over age 60 experience knee pain related to osteoarthritis, the most common disease of the knee joint. Osteoarthritis of the knee causes pain, activity limitation, physical disability, reduced health-related quality of life and excess mortality compared with the general population.

8 Oct 2019

Study receives NCI grant to explore better treatment for brain tumors in children

Children with recurrent brain tumors or newly diagnosed, particularly aggressive tumors called diffuse intrinsic pontine gliomas are being enrolled in the first study to examine the efficacy of a drug that inhibits an enzyme these tumors use to protect themselves from the child's natural immune response.

8 Oct 2019

UA researchers receive $4.1 million grant to study benefits of eyeglasses for toddlers

A team of University of Arizona researchers has received a five-year, $4.1 million grant to study whether using eyeglasses to correct astigmatism in toddlers improves language, cognitive and motor development.

8 Oct 2019

New way to prevent malaria bugs from breeding

A new international collaboration reports that the compound called TCMDC-135051 is capable of preventing the synthesis of a protein that is required for growth in Plasmodium falciparum, one of the species of the Plasmodium parasite that causes malaria. The study, reported in the journal Science, could lead to the development of a new antimalarial drug.

8 Oct 2019

Osaka University Hospital begins clinical research for prostate cancer diagnosis using PET imaging

Osaka University Hospital began Japan's first clinical research for diagnosis of prostate cancer using PET (positron emission tomography) scan results in September 2019.

7 Oct 2019

Deep brain stimulation effective in resistant depression

A new study in the American Journal of Psychiatry says deep brain stimulation is an effective treatment in depressed patients who do not respond to other forms of therapy. The study published on October 4, 2019, looked at the long-term effects on patients who had received electrical stimulation to the subcallosal cingulate area of the brain. The subcallosal cingulate area of the brain is also called Brodmann Area 25, and has been targeted by researchers as a possible focus for antidepressant stimulation.

7 Oct 2019

Novel drug may be the answer in battling resistance in aggressive breast cancer

Breast cancer is one of the most frequently diagnosed cancers in women across the globe. It represents one in four of all cancers in women. The survival rates for breast cancer vary across the globe, but when it comes to the metastatic or advanced breast cancer type, it is currently incurable, but there are many treatments available.

7 Oct 2019

GW researchers to study the underlying pathophysiology of myasthenia gravis

The National Institutes of Health awarded a research team at the George Washington University $7.8 million to establish a rare disease network for myasthenia gravis. The network, which will be part of 25 established NIH Rare Diseases Clinical Research Networks, will include basic and clinical investigators, patient advocacy groups, and biotechnology and pharmaceutical companies working together to enhance therapeutic development for this rare disease.

4 Oct 2019

Penn Medicine awarded $22 million to apply scientific solutions to reverse opioid crisis

The nation has been grappling with the opioid epidemic for years - and the city of Philadelphia has been hit hard by the crisis. While data is showing slight declines in overdose deaths, the opioid crisis remains a public health emergency.

4 Oct 2019

NIH grants boost rare diseases research efforts

Of an estimated 6,500 to 7,000 known rare diseases, only a fraction - maybe 5% - have U.S. Food and Drug Administration-approved treatments.

4 Oct 2019

Scientists uncover the cause of a rare fatal nerve disease

A new study has revealed the cause of Pelizaeus-Merzbacher syndrome and how simply adding a chemical that binds to iron, so it can be removed from the cell, enables the sick cells to grow back.

4 Oct 2019

Kibow Biotech celebrates 22nd anniversary with plans to expand its product portfolio

Kibow® Biotech Inc, a pioneering probiotic company in gut modulation with its novel "Enteric Dialysis®" technology platform, is celebrating its 22-year anniversary on October 1st, 2019.

From Kibow Biotech Inc. 4 Oct 2019

Long-term study data shows DBS is effective for patients with treatment-resistant depression

A study published online on Friday, October 4, in the American Journal of Psychiatry found that deep brain stimulation (DBS) of an area in the brain called the subcallosal cingulate (SCC) provides a robust antidepressant effect that is sustained over a long period of time in patients with treatment-resistant depression--the most severely depressed patients who have not responded to other treatments.

4 Oct 2019

Clinical Trial News and Research

Study evaluates role of PET/CT in selecting candidates for peptide receptor radionuclide therapy

Rice bran supplement for infants provides more nutrients, reduces diarrhea

Differences at the single-cell level can predict responses to BRAF inhibitor therapy

UTHealth: Psychedelic drug being studied to relieve treatment-resistant depression

New experimental growth factor drug appears to prevent worsening of osteoarthritis

Study receives NCI grant to explore better treatment for brain tumors in children

UA researchers receive $4.1 million grant to study benefits of eyeglasses for toddlers

New way to prevent malaria bugs from breeding

Osaka University Hospital begins clinical research for prostate cancer diagnosis using PET imaging

Deep brain stimulation effective in resistant depression

Novel drug may be the answer in battling resistance in aggressive breast cancer

GW researchers to study the underlying pathophysiology of myasthenia gravis

Penn Medicine awarded $22 million to apply scientific solutions to reverse opioid crisis

NIH grants boost rare diseases research efforts

Scientists uncover the cause of a rare fatal nerve disease

Kibow Biotech celebrates 22nd anniversary with plans to expand its product portfolio

Long-term study data shows DBS is effective for patients with treatment-resistant depression

Clinical trial explores effect of whole-body cooling in comatose patients after cardiac arrest

Study shows how caregivers can better manage family conflict at end of life

New test could improve outcomes for patients with sepsis

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer